|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Diflomotecan
|
MedKoo Code#:
201020
|
|
Name:
Diflomotecan
|
|
CAS#:
220997-97-7
Synonym:
BN-80915；BN80915; 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione,
5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5R)-。
IUPAC/Chemical name:
(R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5-dihydrooxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15(1H,13H)-dione
|
|
Chemical structure: |
Theoretical analysis
|
|
|
Chemical Formula: C21H16F2N2O4
Exact Mass: 398.10781
Molecular Weight: 398.35955
m/z: 398.10781 (100.0%), 399.11117 (22.7%),
400.11452 (2.5%)
Elemental Analysis: C, 63.32; H, 4.05; F,
9.54; N, 7.03; O, 16.07
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
Diflomotecan is an E-ring modified camptothecin
analogue, which possesses greater lactone stability in plasma compared
with other topoisomerase I inhibitors. Diflomotecan is also a
10,11-difluoro-homocamptothecin, represents a new promising class of
topoisomerase I inhibitors with enhanced plasma stability and superior
preclinical anti-tumour activity as compared to the established
camptothecins, irinotecan and topotecan. Diflomotecan was the first
homocamptothecin to enter clinical studies. Phase I data are summarized
for both the intravenous and oral schedules. The toxicity is primarily
haematological while no severe gastrointestinal toxicity has been
observed in contrast to other topoisomerase I inhibitors. Diflomotecan
has a high oral bioavailability (72 - 95%) and the oral day 1 - 5 every
3 weeks regimen is recommended for Phase II testing because it is
relatively well tolerated, convenient and mimics protracted exposure.
Current developer:
Biomeasure Inc and Genentech
1: Soto E, Keizer RJ, Trocóniz IF, Huitema AD,
Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C,
Friberg LE, Karlsson MO. Predictive ability of a semi-mechanistic model
for neutropenia in the development of novel anti-cancer agents: two case
studies. Invest New Drugs. 2010 May 7. [Epub ahead of print] PubMed
PMID: 20449627.
2: Kroep JR, Gelderblom H. Diflomotecan, a promising homocamptothecin
for cancer therapy. Expert Opin Investig Drugs. 2009 Jan;18(1):69-75.
Review. PubMed PMID: 19053883.
3: Graham JS, Falk S, Samuel LM, Cendros JM, Evans TR. A multi-centre
dose-escalation and pharmacokinetic study of diflomotecan in patients
with advanced malignancy. Cancer Chemother Pharmacol. 2009
Apr;63(5):945-52. Epub 2008 Jul 25. PubMed PMID: 18654747.
4: Teicher BA. Next generation topoisomerase I inhibitors: Rationale and
biomarker strategies. Biochem Pharmacol. 2008 Mar 15;75(6):1262-71. Epub
2007 Oct 22. Review. PubMed PMID: 18061144.
5: Liao Z, Robey RW, Guirouilh-Barbat J, To KK, Polgar O, Bates SE,
Pommier Y. Reduced expression of DNA topoisomerase I in SF295 human
glioblastoma cells selected for resistance to homocamptothecin and
diflomotecan. Mol Pharmacol. 2008 Feb;73(2):490-7. Epub 2007 Nov 5.
PubMed PMID: 17984197.
6: Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS,
McGovern D, Principe P, Obach R, Twelves C. A multicentre phase I and
pharmacokinetic study of BN80915 (diflomotecan) administered daily as a
20-min intravenous infusion for 5 days every 3 weeks to patients with
advanced solid tumours. Ann Oncol. 2007 Mar;18(3):569-75. PubMed PMID:
17322542.
7: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40. PubMed PMID: 17235418.
8: Peters R, Althaus M, Diolez C, Rolland A, Manginot E, Veyrat M.
Practical formal total syntheses of the homocamptothecin derivative and
anticancer agent diflomotecan via asymmetric acetate aldol additions to
pyridine ketone substrates. J Org Chem. 2006 Sep 29;71(20):7583-95.
PubMed PMID: 16995662.
9: Glaberman U, Rabinowitz I, Verschraegen CF. Alternative
administration of camptothecin analogues. Expert Opin Drug Deliv. 2005
Mar;2(2):323-33. Review. PubMed PMID: 16296757.
10: Trocňniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire
C, Obach R. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic
analysis of the neutropenic response of intravenous diflomotecan in
patients with advanced malignant tumours. Cancer Chemother Pharmacol.
2006 Jun;57(6):727-35. Epub 2005 Oct 28. PubMed PMID: 16261364.
11: Lavelle F. American Association for Cancer Research 1999: 10-14
April, Philadelphia, Pennsylvania. Expert Opin Investig Drugs. 1999
Jun;8(6):903-9. PubMed PMID: 15992139.
12: Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman
K, Sarkadi B, Bates SE. Single nucleotide polymorphisms modify the
transporter activity of ABCG2. Cancer Chemother Pharmacol. 2005
Aug;56(2):161-72. Epub 2005 Apr 19. PubMed PMID: 15838659.
13: Caponigro F, Basile M, de Rosa V, Normanno N. New drugs in cancer
therapy, National Tumor Institute, Naples, 17-18 June 2004. Anticancer
Drugs. 2005 Feb;16(2):211-21. PubMed PMID: 15655420.
14: Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe
P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in
relation to ABCG2 421C>A genotype. Clin Pharmacol Ther. 2004
Jul;76(1):38-44. PubMed PMID: 15229462.
15: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. PubMed PMID: 15148527.
16: Osheroff N. Diflomotecan. Ipsen. IDrugs. 2004 Mar;7(3):257-63.
Review. PubMed PMID: 15011101.
17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Review. PubMed PMID:
14988742.
18: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods
Find Exp Clin Pharmacol. 2003 Dec;25(10):831-55. PubMed PMID: 14735233.
19: Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ,
Devlin M, van Hooije C, Seguy F, Obach R, Pruńonosa J, Principe P,
Twelves C. Phase I pharmacological and bioavailability study of oral
diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in
adults with solid tumors. Clin Cancer Res. 2003 Sep 15;9(11):4101-7.
PubMed PMID: 14519632.
20: Maneely D. Clinical Trials in Cancer-SMi Conference. 11-12 June
2003, London, UK. IDrugs. 2003 Jul;6(7):650-1. PubMed PMID: 12906014.
21: Lansiaux A, Bailly C. [A symphony for the camptothecins]. Bull
Cancer. 2003 Mar;90(3):239-45. French. PubMed PMID: 12801826.
22: Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and
promising anticancer drugs. Crit Rev Oncol Hematol. 2003
Jan;45(1):91-108. Review. PubMed PMID: 12482574.
23: Ulukan H, Swaan PW. Camptothecins: a review of their
chemotherapeutic potential. Drugs. 2002;62(14):2039-57. Review. PubMed
PMID: 12269849.
24: Lansiaux A, Facompré M, Wattez N, Hildebrand MP, Bal C, Demarquay D,
Lavergne O, Bigg DC, Bailly C. Apoptosis induced by the homocamptothecin
anticancer drug BN80915 in HL-60 cells. Mol Pharmacol. 2001
Sep;60(3):450-61. PubMed PMID: 11502875.
25: Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O,
Lesueur-Ginot L, Bigg DC. Unusual potency of BN 80915, a novel
fluorinated E-ring modified camptothecin, toward human colon carcinoma
cells. Cancer Res. 2001 Apr 1;61(7):2961-7. PubMed PMID: 11306474.
26: Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O,
Kasprzyk PG, Bailly C, Camara J, Bigg DC. The homocamptothecin BN 80915
is a highly potent orally active topoisomerase I poison. Anticancer
Drugs. 2001 Jan;12(1):9-19. PubMed PMID: 11272292.
27: Kehrer DF, Soepenberg O, Loos WJ, Verweij J, Sparreboom A.
Modulation of camptothecin analogs in the treatment of cancer: a review.
Anticancer Drugs. 2001 Feb;12(2):89-105. Review. PubMed PMID: 11261892.
28: Lavergne O, Demarquay D, Kasprzyk PG, Bigg DC. Homocamptothecins:
E-ring modified CPT analogues. Ann N Y Acad Sci. 2000;922:100-11.
Review. PubMed PMID: 11193885.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
